Description
Product Specifications
- Product: Tesamorelin 20mg
- Compound / formulation: Tesamorelin
- Labeled quantity / volume: 20mg per vial
- Physical form: White lyophilized powder
- Research focus: Growth Hormone Research, Endocrine Signaling, Body Composition Research, IGF-1 Regulation
- Available batch identifiers: Blue-violet cap, lot TSM20.223
- SKU: HOP-TESAMORELIN-20MG
- Intended classification: Laboratory research only
Independent Laboratory Testing
Accumark Labs — Lot TSM20.223
- Compound reported: Tesamorelin
- Measured content: 20.141 mg
- Purity: 99.733%
- Sample received: October 30, 2026
- Analysis completed: November 3, 2026
- Report ID: Y82U-TMPL
- View laboratory report
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Scientific Research Background
Growth hormone-releasing hormone, or GHRH, signals the pituitary gland to release growth hormone. The pituitary is a small gland involved in controlling several hormones.
Tesamorelin is a synthetic, stabilized version of GHRH. Researchers study how it affects growth hormone release and a related signal called IGF-1, or insulin-like growth factor 1.
These signals influence how the body uses nutrients and maintains tissues. Researchers have examined their relationship with body composition, including fat around internal organs.
Human trials used pharmaceutical tesamorelin in adults with HIV-associated abdominal fat accumulation. They measured abdominal fat, blood fats, and hormone levels. Findings in this particular group do not establish general weight-loss effects or equivalent results for an independently sourced research vial.
Compound details
- Research classification: GHRH analogue
Clinical Research Observations
1. Why is tesamorelin studied in growth hormone research?
Tesamorelin acts on the growth hormone-releasing hormone pathway, which affects growth hormone and related IGF-1 signals.
What researchers found: Clinical studies have measured changes in hormone-related markers and fat distribution after treatment with the tesamorelin preparation used in the trial.
Why it matters: These findings help researchers investigate how these hormone signals affect body composition in the people studied.
2. What did clinical studies find about abdominal fat?
Researchers studied adults with HIV-associated abdominal fat accumulation.
What researchers found: In a 26-week study involving 412 adults, average visceral abdominal fat decreased 15.2% in the tesamorelin group, compared with a 5.0% increase in the placebo group.
Why it matters: Visceral fat surrounds internal organs and is different from overall body weight or fat directly beneath the skin. The findings concern a specific clinical population.
3. What other measurements did researchers monitor?
The studies assessed more than changes in abdominal fat.
What researchers found: Investigators also monitored triglycerides (a type of blood fat), growth hormone-related measurements, and safety findings.
Why it matters: Evaluating multiple outcomes helps researchers understand both the biological response and the limitations of the evidence.
4. Can these findings be applied to HOP research vials?
The published studies used defined medicines used in the studies.
What researchers found: Their outcomes were established under controlled clinical conditions, not with independently sourced House of Peptides products.
Why it matters: Those results do not establish the same medicine quality, safety, or clinical effects for this research vial.
Published Scientific Research
Falutz et al. (2007) — Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine.
DOI: https://doi.org/10.1056/NEJMoa072375
Falutz et al. (2008) — Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS.
DOI: https://doi.org/10.1097/QAD.0b013e32830a5058
Understanding the Research Findings
The clinical findings above relate to the pharmaceutical materials evaluated in those studies. Identifying the compound does not establish identical formulation, pharmaceutical quality, safety, or clinical outcomes. Although tesamorelin is an active ingredient in FDA-approved medications, House of Peptides’ research product is not FDA-approved or represented as interchangeable or clinically equivalent to those medications.
House of Peptides is not affiliated with or endorsed by the pharmaceutical developers referenced in published studies.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.